South Korea's Pharma & Biotech Industry Thrives on Biologics Investment Surge

July 15, 2024--Researched by Industrial Info Resources (Sugar Land, Texas)--South Korea's pharmaceuticals market has been evolving in recent years, as the nation strives to enhance its biomanufacturing capacity. Biologics, a class of medicines derived from living organisms, are gaining traction owing to their higher specificity, reduced side effects and the ability to target complex diseases. Some of the most popular biologics are mRNA vaccines, monoclonal antibodies, and recombinant proteins, that have been instrumental in advancing treatments for a wide range of medical conditions, including cancer, autoimmune disorders, infectious diseases, and genetic disorders.